Biphasic vesicles for topical delivery of interferon alpha in human volunteers and treatment of patients with human papillomavirus infections

Current Drug Delivery

Volumn 8, Issue 3, 2011, Pages 307-319

  Foldvari, Marianna ^a   Badea, Ildiko ^b   Kumar, Praveen ^c   Wettig, Shawn ^a   Batta, Ravinder ^c   King, Martin J ^c   He, Zhihong ^c   Yeboah, Emmanuel ^d   Gaspar, Kimberly ^c   Hull, Peter ^e   Shear, Neil H ^f  

^a UNIVERSITY OF WATERLOO   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c Helix BioPharma Corp   (Canada)

^d ROYAL UNIVERSITY HOSPITAL   (Canada)

^e UNIVERSITY OF SASKATCHEWAN   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

Biphasic vesicles; Genital warts; HPV; Interferon alpha; Protein delivery; Topical delivery

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; RECOMBINANT ALPHA2B INTERFERON;

ADOLESCENT; ADULT; ARTICLE; CENTRIFUGATION; CLINICAL ARTICLE; CONDYLOMA ACUMINATUM; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; ENCAPSULATION; FATIGUE; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LIPID VESICLE; MALE; NORMAL HUMAN; PAPILLOMAVIRUS INFECTION; PARTICLE SIZE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; X RAY CRYSTALLOGRAPHY; ZETA POTENTIAL;

EID: 79953805091     PISSN: 15672018     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720111795256129     Document Type: Article

References (36)

1. Burchell, AN.; Winer, R.L.; de Sanjosé, S.; Franco, EL. Epidemiology and transmission dynamics of genital HPV infection. Vaccine, 2006, 24(Suppl. 3), S52-S61.
2. Pagliusi, SR.; Dillner, J.; Pawlita, M.; Quint, WGV.; Wheeler, CM.; Ferguson, M. International Standard reagents for harmonization of HPV serology and DNA assays-an update. Vaccine, 2006, 24(SUPPL. 3):S193-S200.
3. Saslow, D.; Castle, PE.; Cox, JT.; Davey, DD.; Einstein, MH.; Ferris, DG.; Goldie, SJ.; Harper, DM.; Kinney, W.; Moscicki, AB.; Noller, KL.; Wheeler, CM.; Ades, T.; Andrews, KS.; Doroshenk, MK.; Kahn, KG.; Schmidt, C.; Shafey, O.; Smith, RA.; Partridge, EE.; Garcia, F. American cancer society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J. Clin., 2007, 57(1), 7-28.
4. IARC. Human papillomavirus: IARC monographs on the evaluation of carcinogenic risks to humans. Lyon: IARC Press, 2007, pp. 678.
5. Tchernev, G. Sexually transmitted papillomavirus infections: epidemiology pathogenesis, clinic, morphology, important differential diagnostic aspects, current diagnostic and treatment options. An. Bras. Dermatol., 2009, 84(4), 377-389.
6. Mezei, M.; Gulasekharam, V. Liposomes--a selective drug delivery system for the topical route of administration. Lotion dosage form. Life Sci., 1980, 26(18), 1473-1477.
7. Foldvari, M.; Gesztes, A.; Mezei, M. Dermal drug delivery by liposome encapsulation: clinical and electron microscopic studies. J. Microencap., 1990, 7(4), 479-489.
8. Foldvari, M.; Moreland, A.; Smith, T. Topical liposomal tetracaine for pain relief of intralesional interferon injections in the treatment of condylomata acuminata. Int. J. Dermatol., 1992, 31(12), 894-895.
9. van den Bergh, BA.; Vroom, J.; Gerritsen, H.; Junginger, HE.; Bouwstra, JA.; Interactions of elastic and rigid vesicles with human skin in vitro: electron microscopy and two-photon excitation microscopy. Biochim. Biophys. Acta., 1999, 1461(1), 155-173.
10. Cevc, G.; Gebauer, D.; Stieber, J.; Schatzlein, A.; Blume, G. Ultraflexible vesicles, Transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin. Biochim. Biophys. Acta, 1998, 1368(2), 201-215.
11. Touitou, E.; Dayan, N.; Bergelson, L.; Godin, B.; Eliaz, M. Ethosomes-novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J. Control. Release, 2000, 65(3), 403-418.
12. King, MJ.; Badea, I.; Solomon, J.; Kumar, P.; Gaspar, KJ.; Foldvari, M. Transdermal delivery of insulin from a novel biphasic lipid system in diabetic rats. Diabetes Technol. Ther., 2002, 4(4), 479-488.
13. Baca-Estrada, ME.; Foldvari, M.; Ewen, C.; Badea, I.; Babiuk, LA. Effects of IL-12 on immune responses induced by transcutaneous immunization with antigens formulated in a novel lipid-based biphasic delivery system. Vaccine, 2000 18(17), 1847-1854.
14. Babiuk, S.; Baca-Estrada, ME.; Pontarollo, R.; Foldvari, M. Topical delivery of plasmid DNA using biphasic lipid vesicles (Biphasix). J. Pharm. Pharmacol., 2002, 54(12), 1609-1614.
15. Foldvari, M. Biphasic vesicles: a novel topical drug delivery system. J. Biomed. Nanotechnol., 2010, 6(5), 543-557.
16. Foldvari, M.; Badea, I.; Kumar, P. Biphasic vesicles: an advanced topical drug delivery system for macromolecules. 2010, (submitted).
17. Foldvari, M.; Badea, I.; Wettig, SD.; Baboolal, D.; Kumar, P.; Haynes, CA.; Creagh, AL. Topical delivery of interferon alpha by biphasic vesicles: evidence for a novel nanopathway across the stratum corneum. Mol. Pharm., 2010, 7(3), 751-762.
18. Rose, DSC.; Maddox, PH.; Brown, DC. Which proliferation markers for routine immunohistology? A comparison of five antibodies. J. Clin. Pathol., 1994, 47, 1010-1014.
19. Schattner, A.; Merlin, G.; Wallach, D. Monitoring of interferon therapy by assay of (2'-5') oligoisoadenylate synthetase in human peripheral white blood cells. J. Interferon. Res., 1981, 1, 587-594.
20. Kumar, P.; Batta, R.; LaBine, G.; Shen, J.; Gaspar, KJ.; Docherty, J.; Foldvari, M. Stabilization of interferon alpha-2b in a topical cream. Pharma. Technol., 2009, 33(7), 80-86.
21. Chen, L.; Yu, Z.; Quinn, PJ. The partition of cholesterol between ordered and fluid bilayers of phosphatidylcholine: a synchrotron Xray diffraction study. Biochim. Biophys. Acta, 2007, 1768(11), 2873-2881.
22. Yu, ZW.; Quinn, PJ. Phase stability of phosphatidylcholines in dimethylsulfoxide solutions. Biophys. J., 1995, 69(4), 1456-1463.
23. Manders, EMM.; Verbeek, FJ.; Aten, JA. Measurement of colocalization of objects in dualcolor confocal images. J. Microsc., 1993, 169, 375-382.
24. Trimble, CL.; Piantadosi, S.; Gravitt, P.; Ronnett, B.; Pizer, E.; Elko, A.; Wilgus, B.; Yutzy, W.; Daniel, R.; Shah, K.; Peng, S.; Hung, C.; Roden, R.; Wu, TC.; Pardoll, D. Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin. Cancer Res., 2005, 11(13), 4717-4723.
25. Coleman, N.; Birley, HD.; Renton, AM.; Hanna, NF.; Ryait, BK.; Byrne, M.; Taylor-Robinson, D.; Stanley, MA. Immunological events in regressing genital warts. Am. J. Clin. Pathol., 1994, 2003, 102(6), 768-774.
26. Stanley, M. Genital human papillomavirus infections--current and prospective therapies. J. Natl. Cancer Inst. Monogr., 2003, (31), 117-124.
27. Rougier, A.; Lotte, C. Predictive Approaches I. The stripping technique. In Shah, V.P.; Maibach, H.I.; Eds. Topical drug bioavailability, bioequivalence and penetration. Plenum Press, New York, 1993, pp. 163-181.
28. Imbertson, LM.; Beaurline, JM.; Couture, AM.; Gibson, SJ.; Smith, RM.; Miller, RL.; Reiter, MJ.; Wagner, TL.; Tomai, MA. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J. Invest Dermatol., 1998, 110(5), 734-739.
29. Arany, I.; Tyring, SK.; Stanley, MA.; Tomai, MA.; Miller, RL.; Smith, MH.; McDermott, DJ.; Slade, HB. Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. Antiviral Res., 1999, 43(1), 55-63.
30. Arany, I.; Tyring, SK.; Brysk, MM.; Stanley, MA.; Tomai, MA.; Miller, RL.; Smith, MH.; McDermott, DJ.; Slade, HB. Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (Imiquimod) in genital warts. Antimicrob. Agents Chemother., 2000, 44(7), 1869-1873.
31. Saiag, P.; Bauhofer, A.; Bouscarat, F.; Aquilina, C.; Ortonne, JP.; Dupin, N.; Mougin, C. Imiquimod 5% cream for external genital or perianal warts in human immunodeficiency virus-positive patients treated with highly active antiretroviral therapy: an open-label, noncomparative study. Br. J. Dermatol., 2009, 161(4), 904-909.
32. Winters, U.; Daayana, S.; Lear, JT.; Tomlinson, AE.; Elkord, E.; Stern, PL.; Kitchener, HC. Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia. Clin. Cancer Res., 2008, 14(16), 5292-5299.
33. Rusconi, S.; Agarossi, A.; Ravasi, L.; Tonta, A.; Conti, M.; Galli, M. Serum 2'-5'-oligoadenylate synthetase levels and clinical response to interferon-ß therapy in women with genital human papillomavirus infection. J. Infect Dis., 1994, 169(5),1112-1115.
34. Radwanski, E.; Perentesis, G.; Jacobs, S.; Oden, E.; Affrime, M.; Symchowicz, S.; Zampaglione, N. Pharmacokinetics of interferon alpha-2b in healthy volunteers. J. Clin. Pharmacol., 1987, 27(5), 432-435.
35. Reichman, RC.; Oakes, D.; Bonnez, W.; Greisberger, C.; Tyring SK, Miller L, Whitley, R.; Carveth H, Weidner M, Krueger G. Treatment of condyloma acuminatum with three different interferons administered intralesionally. A double-blind, placebocontrolled trial. Ann. Intern. Med., 1988, 108(5), 675-679.
36. Ludwig, CU.; Ludwig-Hagemann, R.; Obrist, R.; Obrecht, JP.; Holdener, EE.; Sutter-Melde, C. Improved tolerance of interferon alpha-2a by continuous subcutaneous infusion. Onkologie, 1990, 13(2), 117-122.